1. Home
  2. MIST vs MFC Comparison

MIST vs MFC Comparison

Compare MIST & MFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • MFC
  • Stock Information
  • Founded
  • MIST 2003
  • MFC 1887
  • Country
  • MIST Canada
  • MFC Canada
  • Employees
  • MIST N/A
  • MFC N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • MFC Life Insurance
  • Sector
  • MIST Health Care
  • MFC Finance
  • Exchange
  • MIST Nasdaq
  • MFC Nasdaq
  • Market Cap
  • MIST 53.9M
  • MFC 49.3B
  • IPO Year
  • MIST N/A
  • MFC 1999
  • Fundamental
  • Price
  • MIST $1.11
  • MFC $30.76
  • Analyst Decision
  • MIST Strong Buy
  • MFC Strong Buy
  • Analyst Count
  • MIST 2
  • MFC 2
  • Target Price
  • MIST $9.50
  • MFC $45.50
  • AVG Volume (30 Days)
  • MIST 1.6M
  • MFC 2.0M
  • Earning Date
  • MIST 05-20-2025
  • MFC 05-07-2025
  • Dividend Yield
  • MIST N/A
  • MFC 3.91%
  • EPS Growth
  • MIST N/A
  • MFC 14.95
  • EPS
  • MIST N/A
  • MFC 1.85
  • Revenue
  • MIST N/A
  • MFC $20,887,744,800.00
  • Revenue This Year
  • MIST N/A
  • MFC $35.15
  • Revenue Next Year
  • MIST N/A
  • MFC $5.64
  • P/E Ratio
  • MIST N/A
  • MFC $16.68
  • Revenue Growth
  • MIST N/A
  • MFC 9.27
  • 52 Week Low
  • MIST $0.63
  • MFC $23.30
  • 52 Week High
  • MIST $2.75
  • MFC $33.07
  • Technical
  • Relative Strength Index (RSI)
  • MIST 43.96
  • MFC 54.34
  • Support Level
  • MIST $1.28
  • MFC $30.24
  • Resistance Level
  • MIST $1.32
  • MFC $31.51
  • Average True Range (ATR)
  • MIST 0.12
  • MFC 0.56
  • MACD
  • MIST 0.02
  • MFC 0.13
  • Stochastic Oscillator
  • MIST 27.39
  • MFC 67.77

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About MFC Manulife Financial Corporation

Manulife Financial provides life insurance, annuities, and asset management products to individuals and group customers in Canada, the United States, and Asia. Its investment management business contributes approximately 20% of its earnings and has around CAD 1.05 trillion in assets under management and administration as of the end of 2023. The US business, which primarily operates under the John Hancock brand, contributes about 27% of earnings and is mainly focused on providing insurance products for estate, business, and income protection. The Asia segment provides insurance products and insurance-based wealth accumulation products in over 11 countries and contributes around 30% of earnings. The Canadian business segment contributes approximately 23% of earnings.

Share on Social Networks: